Quantify India-origin share on every portfolio molecule. Where India holds 100% of observable supply, the geopolitical concentration is structural.
India accounted for $8.19B of $8.29B in observable API export value in 2024: 98.7% of the global declared trade record. The next origin (Turkey) was 0.64%. The dependency is structural, not cyclical. The 2025 partial-year reading runs even higher at 99.7%.
A single molecule or the full sourced basket. The output is sized at molecule-destination granularity but rolls up to a single India-dependency score.
India's USD share of observable trade per molecule-destination. Lane HHI overlays. The active-exporter count and top-3 share fold into a single composite signal.
Citation-anchored brief with the India-dependency score, the lane HHI, and a recommended alternate-origin workflow per molecule above the threshold.
India dominates observable global API trade. Where a molecule sits at 100% India-origin in a regulated market, a single regulatory or tariff event can take supply offline.
A 100% India lane with HHI 0.43 has a different playbook than a 100% India lane with HHI 0.95. Both signals matter; both surface in the brief.
India share above 80% on a portfolio molecule triggers the alternate-origin workflow. The AI agent pre-populates with EU, US, or China-origin candidate exporters where they exist.
India's share is rising 31.7% over two years. Lanes deepening toward 100% get an early-warning flag before the structural lock-in completes.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve portfolio molecules with observable trade · share is India-origin USD as fraction of total · 2024 declared trade.
The India-dependency view is the single-country exposure score for any sourced molecule. PharmaDB quantifies India’s USD share of observable trade per molecule-destination, overlays the lane HHI, and recommends an alternate-origin workflow where the share crosses 80%. The view is molecule_country_flow; the join is to lane_competitiveness.
India is the structural majority origin for global API supply. The page surfaces the share so a buyer can take a deliberate position rather than discovering single-country exposure during a disruption. The asymmetry is real, not an artefact of the data.
Chinese export data is sparsely covered in the observable dataset. China surfaces as a major origin for KSMs and intermediates flowing into Indian API production (see molecule_country_sourcing) but Chinese finished-API exports are under-represented in the warehouse.
Sum of declared India-origin USD divided by sum of all-origin USD for that molecule-destination in the shipment year. The view is molecule_country_flow with the export_country filter applied at aggregation time.
It searches the active exporter universe for non-India suppliers on the same molecule with a recent DMF and an active regulatory dossier for the destination. For deep-India molecules, the result is often zero, which converts the workflow into a new-source-qualification project.
Dual-source finds a second exporter on the same lane. India-dependency concentration finds a second origin country. They are independent diversification axes; many portfolios run both in parallel.
Trade aggregates refresh weekly. India share recomputes on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.